Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.
To assess the efficacy and safety of the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin in patients of different ethnicities.



Post hoc analysis of data pooled from four randomized, placebo-controlled, phase 3 studies of adults with inadequately controlled type 2 diabetes mellitus (T2DM).



Once daily oral canagliflozin 100 mg or 300 mg, or placebo.



Efficacy endpoints included change from baseline in HbA1c, body weight (BW), systolic blood pressure (SBP), and lipids at week 26; safety and tolerability were assessed by adverse event reports.



Of the 2,313 patients included in this pooled analysis, 609 self-identified as Hispanic/Latino. Hispanic/Latino patients had a mean age of 54 years, mean duration of T2DM of 7 years, mean HbA1c of 8.1%, mean body mass index of 31.2 kg/m(2), and mean SBP of 126.1 mm Hg. There were more women in the non-Hispanic/Latino cohort (63%) compared with the Hispanic/Latino cohort. Placebo-subtracted changes in HbA1c were -.82% with canagliflozin 100 mg and -.94% with canagliflozin 300 mg in the Hispanic/Latino cohort, which were similar to reductions observed in the non-Hispanic/Latino cohort. Significantly greater dose-related reductions in HbA1c, BW, and SBP were observed with both canagliflozin doses compared with placebo. Canagliflozin was generally well-tolerated. Genital mycotic infections were less frequent in Hispanic/Latino women than in non-Hispanic/Latino women.



The SGLT2 inhibitor canagliflozin was generally well-tolerated and was associated with clinically meaningful reductions in HbA1c, BW, and SBP in both Hispanic/Latino and non-Hispanic/Latino patients with T2DM.
Touchstone Diabetes Center, University of Texas Southwestern Medical School.
Jaime A
JA
Davidson
Seville Medical Center, Downey, CA.
Richard
R
Aguilar
Universidad Autónoma de Nuevo León, Nuevo León, Mexico.
Fernando J
FJ
Lavalle González
Janssen Scientific Affairs, LLC, Raritan, NJ.
Angelina
A
Trujillo
Janssen Research and Development, LLC, Raritan, NJ.
Maria
M
Alba
Janssen Research and Development, LLC, Raritan, NJ.
Ujjwala
U
Vijapurkar
Janssen Research and Development, LLC, Raritan, NJ.
Gary
G
Meininger
D000328:Adult; D000368:Aged; D001794:Blood Pressure; D001835:Body Weight; D000068896:Canagliflozin / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000208:ethnology; D004311:Double-Blind Method; D005260:Female; D006630:Hispanic or Latino; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009181:Mycoses; D016032:Randomized Controlled Trials as Topic
D007004:Hypoglycemic Agents; D000068896:Canagliflozin
Canagliflozin; Efficacy; Glucose Co-transporter Inhibitor; Hispanic; Latino; Safety; Type 2 Diabetes Mellitus